Amarin Corporation PLC (AMRN.A) Quote| Reuters.com
Edition:
United States

Amarin Corporation PLC (AMRN.A)

AMRN.A on American Stock Exchange

2.30USD
22 Sep 2015
Change (% chg)

-- (--)
Prev Close
$2.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

AMRN.A

Chart for AMRN.A

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an... (more)

Overall

Beta: 1.06
Market Cap(Mil.): $366.19
Shares Outstanding(Mil.): 183.10
Dividend: --
Yield (%): --

Financials

  AMRN.A Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -0.81 -- --
ROI: -83.73 -5.72 14.23
ROE: -- -4.83 15.46

BRIEF-Amarin Q1 loss per share $0.16

* Amarin reports first quarter 2016 financial results and provides update on operations

May 05 2016

BRIEF-Amarin Corp says CEO Thero's 2015 total compensation was $12.8 mln

* CEO John F. Thero's 2015 total compensation was $12.8 million versus $2.8 million in 2014 - sec filing

Apr 29 2016

U.S. FDA to allow Amarin to promote fish oil pill for off-label use

Amarin Corp Plc can promote its fish-oil pill for unapproved uses after the U.S. Food and Drug Administration decided not to appeal a judge's ruling that the company has the right under the First Amendment to make truthful and non-misleading statements about its products.

Mar 08 2016

UPDATE 1-U.S. FDA to allow Amarin to promote fish oil pill for off-label use

March 8 Amarin Corp Plc can promote its fish-oil pill for unapproved uses after the U.S. Food and Drug Administration decided not to appeal a judge's ruling that the company has the right under the First Amendment to make truthful and non-misleading statements about its products.

Mar 08 2016

U.S. FDA to allow Amarin to promote fish oil pill for off-label use

March 8 Amarin Corporation Plc can promote its fish-oil pill for unapproved uses after the U.S. Food and Drug Administration decided not to appeal a judge's ruling that the company has the right under the First Amendment to make truthful and non-misleading statements about its products.

Mar 08 2016

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.